Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

Publisher： John Wiley & Sons Inc

E-ISSN： 1463-1326|20|3|620-628

ISSN： 1462-8902

Source： DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.20, Iss.3, 2018-03, pp. : 620-628

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 560-565

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 18, Iss. 10, 2016-10 ,pp. : 1034-1040

John Wiley & Sons Inc

Access to resources Recommend Favorite

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 4, 2015-04 ,pp. : 366-375

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial

By Zeng Zhengpei  

Current Medical Research and Opinion, Vol. 29, Iss. 8, 2013-08 ,pp. : 921-929

Informa Healthcare

Access to resources Recommend Favorite

Treatment satisfaction in people with type 2 diabetes mellitus treated with once‐weekly dulaglutide: data from the AWARD‐1 and AWARD‐3 clinical trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 9, 2015-09 ,pp. : 896-903

John Wiley & Sons Inc

Access to resources Recommend Favorite